Search Results
Mar 3, 2022, 9:17 AM
Fulcrum Therapeutics, Inc. announced its plans to initiate REACH, a Phase 3 clinical trial of losmapimod in people with FSHD, in the second quarter of 2022.
Feb 7, 2022, 3:50 PM
Our Annual Auction is online this year
May 13, 2020, 1:46 PM
Fulcrum amends their Phase 2b trial, ReDUX4, to extend the trial from 24 to 48 weeks, adds an interim analysis for subjects who underwent their 16-week biopsy as originally planned, and adds a 36-week biopsy for patients who cannot undergo their 16-week biopsy.
Apr 2, 2020, 4:08 PM
As a result of the suspension of clinical-trial activity by a number of the Company’s clinical trial sites stemming from the pandemic, the Company is currently assessing the impact to the ReDUX4 clinical trial.
Jan 30, 2020, 8:58 AM
Fulcrum Therapeutics announced that the FDA has granted Orphan Drug Designation to losmapimod, a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor.
Aug 19, 2019, 11:14 AM
Fulcrum Therapeutics Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD.
Jun 5, 2019, 12:32 PM
Dr. Bloch provides a final update on his xenograft mouse model project.
Apr 23, 2019, 5:20 PM
Fulcrum Therapeutics today announced an exclusive worldwide license agreement with GlaxoSmithKline for development and commercialization of the investigational drug losmapimod.
Nov 15, 2017, 8:09 PM
Dr. Bloch provides a brief update of his progress on a xenograft mouse model.
Connect with us on social media